Xywav Maintains Upward Trajectory in Narcolepsy and Idiopathic Hypersomnia Treatment
In the third quarter, low-sodium Xywav grew 30% year-over-year, despite additional competition, with continued adoption across both narcolepsy and idiopathic hypersomnia